In vivo study confirmed that the knockdown of TIGAR leads to the inhibition of the proliferation of cancer cells and increases the sensitivity of these cells to the anti-glycolytic agent 2-deoxy-D-glycose, therefore increasing the apoptosis of leukemia cells in the xenograft mouse model. This evidence concerns the gene TIGAR and leukemia.